Oli Pharma Successfully Certified as a National High-Tech Enterprise in 2025

On November 18, 2025, the High-tech Enterprise Accreditation and Management Network issued a notice to release the public announcement list of the first batch of high-tech enterprises accredited in Jiangsu Province in 2025. Suzhou Olipharma Technology Co., Ltd. successfully made the list with its solid scientific innovation capabilities and R&D strength!

National High-tech Enterprise Recognition is an authoritative endorsement by the state of a company's scientific and technological innovation capabilities. It covers multiple stringent indicators such as core independent intellectual property rights, R&D investment intensity, efficiency of technology transfer, and organizational management systems, serving as an important measure of a company’s technical strength and industry competitiveness. The successful inclusion of Olipharma this time fully demonstrates the company's solid capabilities in the field of nucleic acid drugs.

As a professional CRDMO service provider in the field of medicinal nucleic acids, Olipharma has always been committed to technological innovation and process breakthroughs in the nucleic acid drug sector. It has established five core technology platforms: solid-phase synthesis of nucleic acid drugs, chemical modification and conjugation, process development and analysis, CMC pharmaceutical research, and sgRNA development. The company also possesses a pilot-scale platform that complies with GMP standards. By continuously optimizing processes and upgrading its quality management system, Suzhou Olipharma Technology Co., Ltd. provides comprehensive, high-quality CRDMO services to pharmaceutical companies and biotechnology firms both in China and internationally, earning an excellent reputation within the industry.

In the future, the company will take national high-tech enterprises as a new starting point, adhere to the service philosophy of "compliance, quality, reliability, and efficiency," continue to focus on the core business of nucleic acid drug CRDMO, constantly enhance the full-chain service capabilities, provide global nucleic acid drug research and development enterprises with higher quality and efficient technical solutions, and contribute to the high-quality development of China's nucleic acid drug industry.